Payment overview · 2025
General Payments
$155.40
5 reported records · 4 companies
Healthcare provider profile · identity verified
Nayna Shah, MD
Allopathic & Osteopathic Physicians|Family Medicine · HOUSTON, TX · NPI 1457680076
Verified facts
What the public records show
CMS Open Payments records show Nayna Shah, MD received $155.40 in general payments during 2025 across 5 reported records.
ABBVIE INC. accounted for 38.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Lumigan by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Jardiance by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 176 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $60.26 | 38.8% | 2 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $42.70 | 27.5% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $29.62 | 19.1% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.82 | 14.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $155.40 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AVYCAZ Normalized: avycaz |
Drug | ABBVIE INC. | $60.26 | 2 | 2025 |
Source payment records
|
|||||
| EMBLAVEO Normalized: emblaveo |
Drug | ABBVIE INC. | $60.26 | 2 | 2025 |
Source payment records
|
|||||
| TEFLARO Normalized: teflaro |
Drug | ABBVIE INC. | $60.26 | 2 | 2025 |
Source payment records
|
|||||
| VOWST Normalized: vowst |
Biological | Aimmune Therapeutics, Inc. | $42.70 | 1 | 2025 |
Source payment records
|
|||||
| DALVANCE Normalized: dalvance |
Drug | ABBVIE INC. | $30.61 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $29.62 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $29.62 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $29.62 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $29.62 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 176 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
93 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
176 | 31 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 755 | 93 |
| Gabapentin | Gabapentin | 351 | 47 |
| Amlodipine Besylate | Amlodipine Besylate | 333 | 59 |
| Levothyroxine Sodium | Levothyroxine Sodium | 323 | 36 |
| Metformin Hcl | Metformin Hcl | 322 | 42 |
| Losartan Potassium | Losartan Potassium | 311 | 42 |
| Tamsulosin Hcl | Tamsulosin Hcl | 301 | 35 |
| Lisinopril | Lisinopril | 276 | 45 |
| Pantoprazole Sodium | Pantoprazole Sodium | 225 | 47 |
| Omeprazole | Omeprazole | 222 | 33 |
| Famotidine | Famotidine | 200 | 23 |
| Finasteride | Finasteride | 177 | 20 |
| Eliquis | Apixaban | 176 | 31 |
| Carvedilol | Carvedilol | 162 | 26 |
| Metoprolol Tartrate | Metoprolol Tartrate | 128 | 28 |
| Furosemide | Furosemide | 119 | 31 |
| Memantine Hcl | Memantine Hcl | 114 | 12 |
| Trazodone Hcl | Trazodone Hcl | 114 | 15 |
| Metoprolol Succinate | Metoprolol Succinate | 108 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 104 | 13 |
| Mirtazapine | Mirtazapine | 102 | 15 |
| Latanoprost | Latanoprost | 100 | 11 |
| Simvastatin | Simvastatin | 100 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 96 | 11 |
| Sertraline Hcl | Sertraline Hcl | 94 | suppressed |
| Tradjenta | Linagliptin | 94 | suppressed |
| Jardiance | Empagliflozin | 93 | 11 |
| Glipizide Er | Glipizide | 82 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 76 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 76 | 13 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 73 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 71 | suppressed |
| Bumetanide | Bumetanide | 69 | 25 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 62 | 21 |
| Entresto | Sacubitril/Valsartan | 61 | 11 |
| Potassium Chloride | Potassium Chloride | 53 | suppressed |
| Ezetimibe | Ezetimibe | 52 | suppressed |
| Nifedipine Er | Nifedipine | 52 | 12 |
| Lovastatin | Lovastatin | 51 | suppressed |
| Januvia | Sitagliptin Phosphate | 50 | suppressed |
| Xarelto | Rivaroxaban | 47 | suppressed |
| Levetiracetam | Levetiracetam | 44 | suppressed |
| Metformin Er Osmotic | Metformin Hcl | 44 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 42 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 42 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 42 | suppressed |
| Topiramate | Topiramate | 42 | suppressed |
| Lactulose | Lactulose | 41 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 39 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 39 | suppressed |
| Spironolactone | Spironolactone | 39 | suppressed |
| Allopurinol | Allopurinol | 37 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 37 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 35 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 33 | suppressed |
| Prednisone | Prednisone | 33 | 23 |
| Brimonidine Tartrate | Brimonidine Tartrate | 32 | suppressed |
| Digoxin | Digoxin | 32 | suppressed |
| Amantadine | Amantadine Hcl | 31 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 31 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 31 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 30 | 30 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 29 | suppressed |
| Rocklatan | Netarsudil Mesylat/Latanoprost | 28 | suppressed |
| Aripiprazole | Aripiprazole | 27 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 27 | 25 |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 26 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 26 | suppressed |
| Primidone | Primidone | 26 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 25 | suppressed |
| Lumigan | Bimatoprost | 25 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 25 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 25 | 15 |
| Baclofen | Baclofen | 24 | suppressed |
| Fenofibrate | Fenofibrate | 24 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 23 | suppressed |
| Risperidone | Risperidone | 23 | suppressed |
| Travoprost | Travoprost | 23 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 22 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 22 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 21 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 21 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 21 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Lorazepam | Lorazepam | 20 | suppressed |
| Methotrexate | Methotrexate Sodium | 20 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 19 | 19 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Mirabegron Er | Mirabegron | 19 | suppressed |
| Novofine 32 | Pen Needle, Diabetic | 19 | suppressed |
| Atenolol | Atenolol | 18 | suppressed |
| Bupropion Xl | Bupropion Hcl | 18 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 17 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 17 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 17 | suppressed |
| Rhopressa | Netarsudil Mesylate | 17 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Brilinta | Ticagrelor | 15 | suppressed |
| Calcitriol | Calcitriol | 15 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 15 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 15 | suppressed |
| Lamotrigine | Lamotrigine | 15 | suppressed |
| Myrbetriq | Mirabegron | 15 | suppressed |
| Asmanex Hfa | Mometasone Furoate | 14 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 14 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 14 | suppressed |
| Glipizide | Glipizide | 14 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Pregabalin | Pregabalin | 14 | suppressed |
| Premarin | Estrogens, Conjugated | 14 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 14 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Rivastigmine | Rivastigmine | 14 | suppressed |
| Alogliptin | Alogliptin Benzoate | 13 | suppressed |
| Belsomra | Suvorexant | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Briviact | Brivaracetam | 13 | suppressed |
| Calcipotriene | Calcipotriene | 13 | suppressed |
| Cilostazol | Cilostazol | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 11 |
| Crestor | Rosuvastatin Calcium | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 13 | suppressed |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 13 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 13 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 13 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 13 | suppressed |
| Mexiletine Hcl | Mexiletine Hcl | 13 | suppressed |
| Pifeltro | Doravirine | 13 | suppressed |
| Pregabalin Er | Pregabalin | 13 | suppressed |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| Repatha Sureclick | Evolocumab | 13 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 13 | suppressed |
| Tadalafil | Tadalafil | 13 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 13 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Bimatoprost | Bimatoprost | 12 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 12 | suppressed |
| Dulera | Mometasone/Formoterol | 12 | suppressed |
| Levetiracetam Er | Levetiracetam | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Ozempic | Semaglutide | 12 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 11 | 11 |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $155.40 · 5 records | ABBVIE INC. | AVYCAZ, DALVANCE, ELIQUIS, EMBLAVEO, NURTEC ODT, PAXLOVID, TEFLARO, VOWST, ZAVZPRET | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error